(Q34286656)

1 August 2017

The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action (English)

1 reference

1 August 2017

1 reference

1 reference

Oskari Heikinheimo

1

1 reference

PubMed ID

14698071

1 August 2017

Raimo Kekkonen

series ordinal

2

1 reference

PubMed ID

14698071

1 August 2017

Pekka Lähteenmäki

series ordinal

3

1 reference

1 August 2017

1 December 2003

1 reference

1 August 2017

1 reference

1 August 2017

68

1 reference

1 August 2017

6

1 reference

1 August 2017

421-426

1 reference

Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Mifepristone 100 mg in abortion regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

The New Steroid Analog RU 486 Inhibits Glucocorticoid Action in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacokinetic study of orally administered RU 486 in non-pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Plasma concentrations and receptor binding of RU 486 and its metabolites in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Metabolism and serum binding of RU 486 in women after various single doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacokinetics of mifepristone after low oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Distribution of RU 486 and its demethylated metabolites in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Inhibition of ovulation by low-dose mifepristone (RU 486)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Effect of low weekly doses of mifepristone on ovarian function and endometrial development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

Pharmacodynamics of the antiprogesterone RU486 in women after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2803%2900077-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0010-7824(03)00077-5

1 reference

1 August 2017

1 reference

PubMed ID

14698071